Galafold Oral Chaperone Therapy Reimbursed in Canada

The Canadian Drug Expert Committee (CDEC) and INESSS (Quebec) have recommended in favour of reimbursement of Galafold for long-term treatment of adults with a confirmed diagnosis of Fabry Disease and who have an amenable mutation.  Funding is now available in all provinces & territories throughout Canada for amenable patients through exceptional access and/or special drug programs that meet the guidelines of Canadian Fabry Disease Treatment eligibility.  For more information please follow-up with your Fabry physician.

For more information on Galafold or Amicus Therapeutics, Inc please visit